The Claim
The type of statin—hydrophilic versus lipophilic—has no influence on the risk of dementia, mild cognitive impairment, or cognitive decline in older adults aged 65 and older over a median follow-up period of 4.7 years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults aged 65 and older, taking hydrophilic statins versus lipophilic statins does not change the risk of developing dementia, mild cognitive impairment, or cognitive decline over a median follow-up of 4.7 years.
See the scientific wording
The type of statin—hydrophilic versus lipophilic—does not influence the risk of dementia, mild cognitive impairment, or cognitive decline in older adults aged 65 and older over a median follow-up of 4.7 years.
Whether a statin can enter the brain or not, it does not change how the brain manages its cholesterol or controls inflammation, so the risk of memory problems stays the same.
What the research says
1 studyStudy: Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults
The study found that older adults who took statins that can enter the brain were just as likely to develop memory problems or dementia as those who took statins that can’t enter the brain — so the type of statin doesn’t seem to matter for brain health over nearly five years.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.